VHL and neoplasm: We propose that if a common policy for follow-up of patients with VHL mutation-negative isolated CNS haemangioblastoma is to be adopted, then current evidence would suggest that patients should be kept under surveillance until age 50 years (though a small number of individuals would present with a second tumour at a later age).